MEI KUEN ERICA TO: Open Payments
NPI 1114507506 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,668 in 157 payments from 40 companies in 2025. Trend: 2023 $691 · 2024 $6,735 · 2025 $5,668
Food & beverage: $5,074Long term medical supply or device loan: $399Education: $195
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $679 |
| AstraZeneca Pharmaceuticals LP | 15 | $636 |
| Janssen Biotech, Inc. | 10 | $595 |
| Daiichi Sankyo Inc. | 20 | $515 |
| Incyte Corporation | 8 | $273 |
| ABBVIE INC. | 9 | $260 |
| E.R. Squibb & Sons, L.L.C. | 2 | $259 |
| Stemline Therapeutics Inc. | 5 | $216 |
| Merck Sharp & Dohme LLC | 7 | $167 |
| Eisai Inc. | 6 | $159 |
Products named: ENHERTU, KISQALI, RYBREVANT, JAKAFI, Orserdu, DATROWAY, REBLOZYL, Lenvima.
Industry payments across WA — which companies pay providers there.
